Education/CredentialsFellowship: Washington University School of Medicine (Gynecologic Oncology)Residency: Good Samaritan Hospital (Obstetrics and Gynecology)Medical Degree: University of Cincinnati (Obstetrics and Gynecology Gynecologic Oncology)Bachelor's Degree: Miami University (Zoology) Board Certifications & LicensesAmerican Board of Obstetrics and Gynecology (Gynecologic Oncology) (Certification Date: 1997-04-09) - (Recertification Date: 2023-12-31)American Board of Obstetrics and Gynecology (Certification Date: 1995-11-17) - (Recertification Date: 2023-12-31) SpecialtiesGynecologic OncologyObstetrics and Gynecology Contact Information Medical Sciences Building 2005H Office 513-558-2177 Email herzogtj@ucmail.uc.edu Clinical Interests Gynecologic OncologyObstetrics and GynecologyOncologyAdenomyosisAdnexal DiseaseAdnexal TumorsCervical CancerDysgerminomaEmbryonal CarcinomaEmbryonal TumorsEndometrial CancerEndometrial Stromal SarcomaEndometriosisFallopian Tube CancerFibroidsGerm Cell and Embryona CancersGerm Cell TumorGestational Trophoblastic NeoplasiaHuman Papilloma Virus (HPV)Krukenberg TumorOther Complicated Gynecologic CancersOvarian CancerOvarian CystPelvic CancersPelvic MassesPlacenta AccretaPrecancer in the VaginaPrecancer in the VulvaPrecancers in the CervixUterine Fibroids (Uterine leiomyoma)Uterine HemorrhageUterine Polyps (Endometrial Polyps)Uterine SarcomaVaginal CancerVulvar Cancer Peer Reviewed Publications Du Bois A.;Floquet A.;Kim J.W.;Rau J.;Del Campo J.M.;Friedlander M.;Pignata S.;Fujiwara K.;Vergote I.;Colombo N.;Mirza M.R.;Monk B.J.;Kimmig R.;Ray-Coquard I.;Zang R.;Diaz-Padilla I.;Baumann K.H.;Mouret-Reynier M.A.;Kim J.H.;Kurzeder C.;Lesoin A.;Vasey P.;Marth C.;Canzler U.;Scambia G.;Shimada M.;Calvert P.;Pujade-Lauraine E.;Kim B.G.;Herzog T.J.;Mitrica I.;Schade-Brittinger C.;Wang Q.;Crescenzo R.;Harter P. 10-20-2014. Incorporation of pazopanib in maintenance therapy of ovarian cancer Journal of Clinical Oncology, 32 30, 3374-3381Herzog T.;Coleman R.;Monk B.;Armstrong D.;Alvarez R. 05-01-2015. In assessing surrogate clinical trial end points: Drug safety is a requisite Journal of Clinical Oncology, 33 13, 1511-1512Floquet A.;Vergote I.;Colombo N.;Fiane B.;Monk B.J.;Reinthaller A.;Calvert P.;Herzog T.J.;Meier W.;Kim J.W.;Campo J.M.D.;Friedlander M.;Pisano C.;Isonishin S.;Crescenzo R.J.;Barrett C.;Wang K.;Mitrica I.;Bois A.D. 01-01-2015. Progression-free survival by local investigator versus independent central review: Comparative analy Gynecologic Oncology, 136 1, 37-42Jackson A.;Eisenhauer E.;Herzog T. 01-01-2015. Emerging therapies: Angiogenesis inhibitors for ovarian cancer Expert Opinion on Emerging Drugs, 20 2, 331-346Previs R.;Leath C.;Coleman R.;Herzog T.;Krivak T.;Brower S.;Tian C.;Secord A. 01-01-2015. Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian ca Gynecologic Oncology, 138 2, 267-271Berek J.S.;Edwards R.P.;Parker L.P.;Demars L.R.;Herzog T.J.;Lentz S.S.;Morris R.T.;Akerley W.L.;Holloway R.W.;Method M.W.;Plaxe S.C.;Walker J.L.;Friccius-Quecke H.;Krasner C.N. 01-01-2014. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian International Journal of Gynecological Cancer, 24 9, 1583-1589Burke W.M.;Orr J.;Leitao M.;Salom E.;Gehrig P.;Olawaiye A.B.;Brewer M.;Boruta D.;Villella J.;Herzog T.;Shahin F.A. 01-01-2014. Corrigendum to "Endometrial cancer: A review and current management strategies: Part I" [Gynecol Onc Gynecologic Oncology, 135 3, 625Herzog T.J.;Monk B.J.;Rose P.G.;Braly P.;Hines J.F.;Bell M.C.;Wenham R.M.;Secord A.A.;Roman L.D.;Einstein M.H.;Drake R.D.;Childs B.H. 01-01-2014. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer Gynecologic Oncology, 132 3, 517-525Wright J.;Ananth C.;Tsui J.;Glied S.;Burke W.;Lu Y.;Neugut A.;Herzog T.;Hershman D. 01-01-2014. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer Cancer, 120 8, 1246-1254
Clinical Interests Gynecologic OncologyObstetrics and GynecologyOncologyAdenomyosisAdnexal DiseaseAdnexal TumorsCervical CancerDysgerminomaEmbryonal CarcinomaEmbryonal TumorsEndometrial CancerEndometrial Stromal SarcomaEndometriosisFallopian Tube CancerFibroidsGerm Cell and Embryona CancersGerm Cell TumorGestational Trophoblastic NeoplasiaHuman Papilloma Virus (HPV)Krukenberg TumorOther Complicated Gynecologic CancersOvarian CancerOvarian CystPelvic CancersPelvic MassesPlacenta AccretaPrecancer in the VaginaPrecancer in the VulvaPrecancers in the CervixUterine Fibroids (Uterine leiomyoma)Uterine HemorrhageUterine Polyps (Endometrial Polyps)Uterine SarcomaVaginal CancerVulvar Cancer
Peer Reviewed Publications Du Bois A.;Floquet A.;Kim J.W.;Rau J.;Del Campo J.M.;Friedlander M.;Pignata S.;Fujiwara K.;Vergote I.;Colombo N.;Mirza M.R.;Monk B.J.;Kimmig R.;Ray-Coquard I.;Zang R.;Diaz-Padilla I.;Baumann K.H.;Mouret-Reynier M.A.;Kim J.H.;Kurzeder C.;Lesoin A.;Vasey P.;Marth C.;Canzler U.;Scambia G.;Shimada M.;Calvert P.;Pujade-Lauraine E.;Kim B.G.;Herzog T.J.;Mitrica I.;Schade-Brittinger C.;Wang Q.;Crescenzo R.;Harter P. 10-20-2014. Incorporation of pazopanib in maintenance therapy of ovarian cancer Journal of Clinical Oncology, 32 30, 3374-3381Herzog T.;Coleman R.;Monk B.;Armstrong D.;Alvarez R. 05-01-2015. In assessing surrogate clinical trial end points: Drug safety is a requisite Journal of Clinical Oncology, 33 13, 1511-1512Floquet A.;Vergote I.;Colombo N.;Fiane B.;Monk B.J.;Reinthaller A.;Calvert P.;Herzog T.J.;Meier W.;Kim J.W.;Campo J.M.D.;Friedlander M.;Pisano C.;Isonishin S.;Crescenzo R.J.;Barrett C.;Wang K.;Mitrica I.;Bois A.D. 01-01-2015. Progression-free survival by local investigator versus independent central review: Comparative analy Gynecologic Oncology, 136 1, 37-42Jackson A.;Eisenhauer E.;Herzog T. 01-01-2015. Emerging therapies: Angiogenesis inhibitors for ovarian cancer Expert Opinion on Emerging Drugs, 20 2, 331-346Previs R.;Leath C.;Coleman R.;Herzog T.;Krivak T.;Brower S.;Tian C.;Secord A. 01-01-2015. Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian ca Gynecologic Oncology, 138 2, 267-271Berek J.S.;Edwards R.P.;Parker L.P.;Demars L.R.;Herzog T.J.;Lentz S.S.;Morris R.T.;Akerley W.L.;Holloway R.W.;Method M.W.;Plaxe S.C.;Walker J.L.;Friccius-Quecke H.;Krasner C.N. 01-01-2014. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian International Journal of Gynecological Cancer, 24 9, 1583-1589Burke W.M.;Orr J.;Leitao M.;Salom E.;Gehrig P.;Olawaiye A.B.;Brewer M.;Boruta D.;Villella J.;Herzog T.;Shahin F.A. 01-01-2014. Corrigendum to "Endometrial cancer: A review and current management strategies: Part I" [Gynecol Onc Gynecologic Oncology, 135 3, 625Herzog T.J.;Monk B.J.;Rose P.G.;Braly P.;Hines J.F.;Bell M.C.;Wenham R.M.;Secord A.A.;Roman L.D.;Einstein M.H.;Drake R.D.;Childs B.H. 01-01-2014. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer Gynecologic Oncology, 132 3, 517-525Wright J.;Ananth C.;Tsui J.;Glied S.;Burke W.;Lu Y.;Neugut A.;Herzog T.;Hershman D. 01-01-2014. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer Cancer, 120 8, 1246-1254
Du Bois A.;Floquet A.;Kim J.W.;Rau J.;Del Campo J.M.;Friedlander M.;Pignata S.;Fujiwara K.;Vergote I.;Colombo N.;Mirza M.R.;Monk B.J.;Kimmig R.;Ray-Coquard I.;Zang R.;Diaz-Padilla I.;Baumann K.H.;Mouret-Reynier M.A.;Kim J.H.;Kurzeder C.;Lesoin A.;Vasey P.;Marth C.;Canzler U.;Scambia G.;Shimada M.;Calvert P.;Pujade-Lauraine E.;Kim B.G.;Herzog T.J.;Mitrica I.;Schade-Brittinger C.;Wang Q.;Crescenzo R.;Harter P. 10-20-2014. Incorporation of pazopanib in maintenance therapy of ovarian cancer Journal of Clinical Oncology, 32 30, 3374-3381Herzog T.;Coleman R.;Monk B.;Armstrong D.;Alvarez R. 05-01-2015. In assessing surrogate clinical trial end points: Drug safety is a requisite Journal of Clinical Oncology, 33 13, 1511-1512Floquet A.;Vergote I.;Colombo N.;Fiane B.;Monk B.J.;Reinthaller A.;Calvert P.;Herzog T.J.;Meier W.;Kim J.W.;Campo J.M.D.;Friedlander M.;Pisano C.;Isonishin S.;Crescenzo R.J.;Barrett C.;Wang K.;Mitrica I.;Bois A.D. 01-01-2015. Progression-free survival by local investigator versus independent central review: Comparative analy Gynecologic Oncology, 136 1, 37-42Jackson A.;Eisenhauer E.;Herzog T. 01-01-2015. Emerging therapies: Angiogenesis inhibitors for ovarian cancer Expert Opinion on Emerging Drugs, 20 2, 331-346Previs R.;Leath C.;Coleman R.;Herzog T.;Krivak T.;Brower S.;Tian C.;Secord A. 01-01-2015. Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian ca Gynecologic Oncology, 138 2, 267-271Berek J.S.;Edwards R.P.;Parker L.P.;Demars L.R.;Herzog T.J.;Lentz S.S.;Morris R.T.;Akerley W.L.;Holloway R.W.;Method M.W.;Plaxe S.C.;Walker J.L.;Friccius-Quecke H.;Krasner C.N. 01-01-2014. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian International Journal of Gynecological Cancer, 24 9, 1583-1589Burke W.M.;Orr J.;Leitao M.;Salom E.;Gehrig P.;Olawaiye A.B.;Brewer M.;Boruta D.;Villella J.;Herzog T.;Shahin F.A. 01-01-2014. Corrigendum to "Endometrial cancer: A review and current management strategies: Part I" [Gynecol Onc Gynecologic Oncology, 135 3, 625Herzog T.J.;Monk B.J.;Rose P.G.;Braly P.;Hines J.F.;Bell M.C.;Wenham R.M.;Secord A.A.;Roman L.D.;Einstein M.H.;Drake R.D.;Childs B.H. 01-01-2014. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer Gynecologic Oncology, 132 3, 517-525Wright J.;Ananth C.;Tsui J.;Glied S.;Burke W.;Lu Y.;Neugut A.;Herzog T.;Hershman D. 01-01-2014. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer Cancer, 120 8, 1246-1254